<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020189</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068028</org_study_id>
    <secondary_id>NCI-00-C-0128</secondary_id>
    <secondary_id>MB-401</secondary_id>
    <secondary_id>NCI-T99-0066</secondary_id>
    <nct_id>NCT00020189</nct_id>
    <nct_alias>NCT00005670</nct_alias>
  </id_info>
  <brief_title>Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer</brief_title>
  <official_title>A Phase II Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who&#xD;
      have recurrent or metastatic head and neck cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the standard response rate (complete response and partial response) and&#xD;
           duration of response in patients with recurrent or metastatic squamous cell carcinoma of&#xD;
           the head and neck treated with flavopiridol.&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxic effects of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the progression-free and overall survival of patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the effects of anti-platelet agents, aspirin and clopidogrel bisulfate, on the&#xD;
           pharmacology of flavopiridol in these patients.&#xD;
&#xD;
        -  Determine the effects of prophylactic anticoagulation with anti-platelet agents, aspirin&#xD;
           and clopidogrel bisulfate, on the incidence of flavopiridol-related thrombosis in these&#xD;
           patients.&#xD;
&#xD;
      OUTLINE: Patients receive flavopiridol IV over 1 hour on days 1-5. Courses repeat every 3&#xD;
      weeks in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients also receive oral aspirin and clopidogrel bisulfate beginning on day 0 and&#xD;
      continuing throughout the study.&#xD;
&#xD;
      Patients are followed until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 1-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">August 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Head and Neck Cancer</condition>
  <condition>Thromboembolism</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetylsalicylic acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel bisulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven squamous cell carcinoma of the head and neck&#xD;
&#xD;
               -  Metastatic disease at diagnosis OR&#xD;
&#xD;
               -  Persistent, metastatic, or recurrent disease after prior definitive surgery&#xD;
                  and/or radiotherapy&#xD;
&#xD;
          -  No undifferentiated and nonkeratinizing carcinomas, including lymphoepitheliomas of&#xD;
             all locations&#xD;
&#xD;
          -  No nasopharynx tumors&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
               -  Patients whose only measurable disease is within a prior radiotherapy port must&#xD;
                  have clearly progressive disease&#xD;
&#xD;
          -  No metastatic or leptomeningeal CNS disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Absolute granulocyte count greater than 1,500/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  See Other (Prior/Concurrent Therapy)&#xD;
&#xD;
          -  SGOT and SGPT less than 2.5 times normal&#xD;
&#xD;
          -  Bilirubin less than 1.5 times normal&#xD;
&#xD;
          -  No history of hypercoagulopathies (e.g., protein C deficiency, protein S deficiency,&#xD;
             or lupus anticoagulant)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  Calcium no greater than normal&#xD;
&#xD;
          -  No hypercalcemia refractory to bisphosphonates&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No unstable or newly diagnosed angina pectoris&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No class II-IV congestive heart failure&#xD;
&#xD;
          -  No history of symptomatic carotid disease&#xD;
&#xD;
          -  No concurrent asymptomatic carotid artery occlusion (70% or greater) in one or both&#xD;
             arteries by Doppler ultrasound&#xD;
&#xD;
          -  No symptomatic atherosclerosis&#xD;
&#xD;
          -  No thrombotic events within the past 6 months&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No aspirin-induced asthma&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No inability to take aspirin or clopidogrel bisulfate due to contraindications,&#xD;
             allergies, or pre-existing medical conditions (e.g., active peptic ulcer disease or&#xD;
             history of undiagnosed non-occult, non-hemorrhoidal gastrointestinal or other bleeding&#xD;
             sources within the past 6 months)&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except adequately treated basal cell&#xD;
             or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated&#xD;
             stage I or II cancer that is currently in complete remission&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
          -  No prior flavopiridol&#xD;
&#xD;
          -  No more than 3 prior systemic chemotherapy regimens for recurrent or metastatic&#xD;
             disease&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy except oral contraceptives&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior surgery and recovered&#xD;
&#xD;
          -  No prior carotid endarterectomy or other revascularization surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent antineoplastic therapies&#xD;
&#xD;
          -  No active anticoagulation with INR 1.5 or greater&#xD;
&#xD;
          -  No low-molecular weight heparin or equivalent&#xD;
&#xD;
          -  Concurrent bisphosphonates for calcium maintenance allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara A. Conley, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2004</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>thromboembolism</keyword>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>metastatic squamous neck cancer with occult primary squamous cell carcinoma</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>salivary gland squamous cell carcinoma</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

